| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.17 | 9e-08 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-06 |